Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Blood bag standards need revising, say French:

This article was originally published in Clinica

Executive Summary

The French healthcare products safety agency, AFSSAPS, has called for a change in existing international standards for the compatibility of transfusion tubing devices with blood bags following "numerous incidents" where the bags have punctured on insertion of the tubing. This has occurred despite the existence of two international standards that in theory guarantee the compatibility of the two components. Bag punctures result in a potentially hazardous leakage of blood. The problems could be occurring because healthcare professionals are using too much force when inserting the tubing, in which case a cover on the perforating end of the tubing could help minimise the problem, the French agency suggests.

You may also be interested in...



Who’s Hired? Hikma Recruits New US Generics President

A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.

Organon And Henlius Complete Phase III For Denosumab

Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.

Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims

Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT064927

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel